Medical News


Regional Chemotherapy Saves 2 Toronto Men

Regional Chemotherapy Saves Two Toronto Men

Christmas came early for Gerald Kopitowski – in July he was given four months to live after being diagnosed with aggressive oral cancer that ravaged his tongue and throat, preventing him from eating and talking, and eventually breathing. He lost 80 lbs. in mere months.





FDA Approved

FDA Approves Eucrisa For Eczema

The U.S. Food and Drug Administration today approved Eucrisa (crisaborole) ointment to treat mild to moderate eczema (atopic dermatitis) in patients two years of age and older.


Fda Approves First Autologous Cellularized Scaffold For The Repair of Cartilage Defects of The Knee

FDA Approves First Autologous Cellularized Scaffold For The Repair of Cartilage Defects of The Knee

The U.S. Food and Drug Administration today approved Maci (autologous cultured chondrocytes on porcine collagen membrane) for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients. Maci is the first FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee.


Laugh Lines

FDA Approval of Two Dermal Fillers for Treatment of “Laugh Lines”

Galderma, a global leader focused on medical solutions in skin health, has announced that it has received U.S. Food and Drug Administration (FDA) approval of two new products for the treatment of nasolabial folds (NLF) or “laugh lines,” in patients over the age of 21.1,2 Restylane® Refyne was approved for the treatment of moderate to severe facial wrinkles and folds and Restylane® Defyne for the treatment of moderate to severe, deep facial wrinkles and folds.1,2